Ryan Gentzler, MD
Medical Oncology · Charlottesville, VANPI 1235390444
Payments from drug & device makers
Across 381 payments — averaging $14,593 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1.5M
- Amgen$1.5M
- Janssen Research & Development, LLC$897K
- Takeda Pharmaceuticals U.S.A., Inc.$472K
- Pfizer$347K
- AstraZeneca$252K
- plus $608K from 20 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 142 | $1,523,946 |
| Amgen | 11 | $1,459,049 |
| Janssen Research & Development, LLC | 57 | $897,304 |
| Takeda Pharmaceuticals U.S.A., Inc. | 65 | $472,476 |
| Pfizer | 6 | $347,435 |
| AstraZeneca | 22 | $251,527 |
| Chugai Pharmaceutical Co., Ltd. | 9 | $184,381 |
| Daiichi Sankyo Inc. | 22 | $163,996 |
| Puma Biotechnology, Inc. | 8 | $75,914 |
| Astrazeneca UK Limited | 5 | $51,330 |
| Helsinn Healthcare SA | 6 | $41,374 |
| Eli Lilly | 4 | $38,966 |
| E.r. Squibb & Sons, L.L.C. | 3 | $29,364 |
| Boehringer Ingelheim | 1 | $3,553 |
| Organon | 2 | $3,000 |
| Regeneron | 5 | $2,675 |
| Gilead | 1 | $2,570 |
| Sanofi | 1 | $2,289 |
| Blueprint Medicines Corporation | 1 | $2,256 |
| Genentech USA, Inc. | 3 | $1,901 |
| Janssen Scientific Affairs, LLC | 1 | $1,768 |
| Jazz Pharmaceuticals Inc. | 1 | $1,400 |
| AbbVie | 2 | $1,088 |
| Tempus AI, Inc | 1 | $146 |
| Regeneron Healthcare Solutions, Inc. | 1 | $48 |
| Taiho Oncology, Inc. | 1 | $42 |
How this compares
$5,559,796 in reported general payments places this provider in the 95th percentile of 95 medical oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Charlottesville
- Robert DreicerCharlottesville$5.4M
- Matthew ReilleyCharlottesville$3.8M
- Patrick DillonCharlottesville$2.6M
- Varinder KaurCharlottesville$2.4M
- Richard HallCharlottesville$1.7M
- Enrica MarchiCharlottesville$1.2M
- Paul KunkCharlottesville$669K
- Ludimila CavalcanteCharlottesville$525K
- Tri leCharlottesville$323K
- Trish MillardCharlottesville$244K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.